Long Non-coding RNA ST8SIA6-AS1 Promotes Lung Adenocarcinoma Progression Through Sponging miR-125a-3p

Qifeng Cao; Weiqin Yang; Xili Ji; Wei Wang

doi:10.3389/fgene.2020.597795

Long Non-coding RNA ST8SIA6-AS1 Promotes Lung Adenocarcinoma Progression Through Sponging miR-125a-3p

Front Genet. 2020 Dec 8:11:597795. doi: 10.3389/fgene.2020.597795. eCollection 2020.

Authors

Qifeng Cao¹, Weiqin Yang², Xili Ji³, Wei Wang⁴

Affiliations

¹ Department of Respiratory Medicine, Taizhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenling, China.
² Department of Gastroenterology, Taizhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenling, China.
³ Department of Pulmonary Disease, Jinan Traditional Chinese Medicine Hospital, Jinan, China.
⁴ Cheeloo College of Medicine, Shandong University, Jinan, China.

Abstract

Emerging evidence suggests that long non-coding RNA (lncRNA) plays a critical role in human disease progression. Recently, a novel lncRNA ST8SIA6-AS1 was shown as an important driver in various cancer types. Nevertheless, its contribution to lung adenocarcinoma (LUAD) remains undocumented. Herein, we found that ST8SIA6-AS1 was frequently overexpressed in LUAD cell lines, tissues, and plasma. Depletion of ST8SIA6-AS1 significantly inhibited LUAD cell proliferation and invasion in vitro and tumor growth in vivo. In term of mechanism, ST8SIA6-AS1 was transcriptionally repressed by tumor suppressor p53, and ST8SIA6-AS1 was mainly located in the cytoplasm and could abundantly sponge miR-125a-3p to increase nicotinamide N-methyltransferase (NNMT) expression, thereby facilitating LUAD malignant progression. Clinically, high ST8SIA6-AS1 was positively correlated with larger tumor size, lymph node metastasis, and later TNM stage. Moreover, ST8SIA6-AS1 was identified as an excellent indicator for MM diagnosis and prognosis. Collectively, our data demonstrate that ST8SIA6-AS1 is a carcinogenic lncRNA in LUAD, and targeting the axis of ST8SIA6-AS1/miR-125a-3p/NNMT may be a promising treatment for LUAD patients.

Keywords: biomarker; long non-coding RNA; lung adenocarcinoma; p53; transcriptional regulation.